**Pharmaceutical Products:** 70%
**Biotechnology:** 20%
**Licensing Fees and Partnerships:** 10%

**TOP 3 Markets:**
**South Korea:** 45%
**USA:** 30%
**Japan:** 15%

Hanall Biopharma Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, accounting for approximately 70% of total revenue. The biotechnology sector contributes 20%, while licensing fees and partnerships make up the remaining 10%.

In terms of the geographical distribution of revenue, South Korea is the largest market for Hanall Biopharma, followed by the USA and Japan. These three markets together account for the majority of the company's revenue, with South Korea contributing almost half of the revenue.

**Production Sites:** South Korea

Hanall Biopharma Co., Ltd. mainly produces its products in South Korea. The company operates modern production facilities there that meet the high quality standards of the pharmaceutical industry. This strategic location enables Hanall Biopharma to efficiently respond to demand in the Asian market while also taking advantage of export opportunities.

**Focus on Research and Development:** 25% of revenue (estimated for 2026)
**Planned Market Expansion:** Entry into the US and European markets by 2027

Hanall Biopharma Co., Ltd. pursues a strategy that is heavily focused on research and development (R&D). The company invests an estimated 25% of its revenue in R&D to develop innovative biopharmaceutical products. These investments aim to expand the company's pipeline with new drugs, particularly in the fields of immunology and oncology.

Another strategic focus is on international expansion. Hanall Biopharma plans to enter the US and European markets by 2027. This expansion will be supported through partnerships with local companies and the establishment of its own distribution channels. The goal is to strengthen global presence and tap into new revenue sources.

Additionally, the company relies on strategic alliances and licensing agreements to expand its product range and accelerate market entry. This strategy is intended to help Hanall Biopharma grow in a competitive market environment and solidify its market position.

**Key Commodities:** Biopharmaceutical active ingredients, excipients, packaging materials
**Main Import Countries:** USA, Germany, China

Hanall Biopharma Co., Ltd. imports a variety of commodities necessary for the production of their biopharmaceutical products. This includes especially biopharmaceutical active ingredients and excipients that are essential for medication production.

The USA and Germany are important suppliers of high-quality pharmaceutical active ingredients and technologies used in production. China often supplies more cost-effective commodities and packaging materials, which also play a role in Hanall Biopharma's production.

These international procurement markets enable Hanall Biopharma to manufacture high-quality products and remain competitive.

**Market Share:** Estimated 5-7% in the Asian biopharma market (2026)
**Research & Development (R&D) Expenses:** 15% of revenue (2025)
**Patent Portfolio:** Over 50 active patents (2026)

Hanall Biopharma Co., Ltd. has established itself as a significant player in the Asian biopharma market in recent years. The company's competitive advantage lies in its strong R&D focus, accounting for approximately 15% of revenue. This enables Hanall to continuously develop new and innovative therapies.

Another element of the competitive advantage is the extensive patent portfolio, which includes over 50 active patents. This protects the company from imitators and secures exclusive market positions for its products.

In addition, Hanall Biopharma has formed strategic partnerships and alliances with international pharmaceutical companies, facilitating access to new markets and strengthening global presence. Together, these factors give the company a solid competitive edge in the industry.

**Institutional Investor Share:** Estimated at about 45% (2026)

**Insider Buys/Sells:** No significant transactions in the last year (2026)

The institutional investor share in Hanall Biopharma Co., Ltd. is estimated to be around 45%. This demonstrates a strong confidence from institutional investors in the company, which often indicates a positive outlook on future business development.

In 2026, there were no significant insider buys or sells, which could suggest a stable assessment from the management regarding the current company valuation and future business prospects.

**Market share of Hanall Biopharma:** Estimated 3-5% (2026)

**Top competitors and their market shares:**
1. **Samsung Biologics:** 15%
2. **Celltrion:** 12%
3. **LG Chem:** 10%
4. **SK Biopharmaceuticals:** 8%
5. **Hanmi Pharmaceutical:** 7%
6. **Hanall Biopharma:** 3-5%
7. **Daewoong Pharmaceutical:** 3%
8. **GC Pharma:** 2.5%
9. **Yuhan Corporation:** 2%
10. **Dong-A ST:** 1.5%

**Moat of Hanall Biopharma:**

Hanall Biopharma has a moderate moat, mainly based on specialized research and development as well as strategic partnerships. Compared to larger competitors like Samsung Biologics and Celltrion, which have more extensive resources and broader product portfolios, Hanall's moat is less pronounced.

Samsung Biologics and Celltrion have significant advantages due to their production capacities and global presence. These companies benefit from economies of scale and a strong international market position, giving them a stronger moat.

Hanall Biopharma could strengthen its moat through investments in innovative technologies and the exploration of new markets. Focus on niche products and targeted collaborations could also help increase competitiveness.

**Revenue Growth:** Estimated 8% (2025)
**Research and Development Ratio:** 15% of revenue (2025)
**Market Share in Asia:** 5% (2025)

Hanall Biopharma Co., Ltd. has experienced solid revenue growth of approximately 8% in recent years. This indicates a stable business development supported by a strong position in the biopharmaceutical industry.

The company invests about 15% of its revenue in research and development, pointing to a strong innovation pipeline. These investments could lead to new product developments and long-term growth potential.

With a market share of 5% in Asia, Hanall Biopharma demonstrates a significant presence in one of the fastest-growing markets in the world. This could position the company advantageously for future expansions.

Overall, Hanall Biopharma appears to be a promising investment, especially for investors interested in long-term growth and looking to capitalize on the potential of new biopharmaceutical developments.

**Dividend payment:** No dividend (2026)

Hanall Biopharma Co., Ltd. has not paid any dividends in recent years. The company is strongly focused on research and development, particularly in the areas of biopharmaceuticals and innovative therapies.

The decision not to pay a dividend could indicate that the company is reinvesting its profits to promote future growth and innovations. This is a common practice in the biotechnology industry, where significant investments in research and development are required.

For investors interested in dividends, this could mean that Hanall Biopharma is currently not the right choice unless they are willing to bet on potential capital growth that could be achieved through successful product developments and market launches.